Idiopathic pulmonary fibrosis (IPF) is a disorder characterized by chronic and progressive scarring of lung tissue. The cause of this disease is currently unknown. However, it can significantly impair one’s quality of life as patients often experience difficulty breathing. The seriousness of this disease makes finding effective treatment of paramount importance. Current pharmacological interventions are riddled with side-effects. Several clinical trials are underway in hopes of finding an effective therapy with little to no side-effects. One of the drugs showing promise as a potential therapeutic for IPF is GB0139 (formerly TD139). Here, we delve deeper into the mechanism by which GB0139 functions and its current status within clinical trials, providing hope for individuals who have been diagnosed with IPF.
GB0139 (formerly TD139) - Specific Articles:
- TD139 for Idiopathic Pulmonary Fibrosis - https://tinyurl.com/r8ewh2qGalecto Biotech’s Lead Molecule TD139 is Safe, Well Tolerated, with Direct Target Engagement and Biomarker Effects in a Clinical Phase Ib/IIa trial in IPF Patients
- Randomized Controlled Trials of GB0139 (formerly TD139): A Study to Test the Efficacy and Safety of Inhaled TD139 in Subjects With Idiopathic Pulmonary Fibrosis (IPF)
- RCT (Randomized Control Trial) of TD139 vs Placebo in HV's (Human Volunteers) and IPF Patients
Hamilton Pulmonary Fibrosis Support
Group Contact: Stephen Binch firstname.lastname@example.org 289-456-7223
Meeting Location: Fortino's Community Room, 1579 Main St West Hamilton, ON L8S 1E6